BioSpace News Archive

Business

MoonLake Immunotherapeutics Reports Second Quarter 2023 Financial Results and Provides a Business Update

MoonLake Immunotherapeutics, a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, announced its financial results for the second quarter of 2023.

August 10, 2023
·
17 min read
Business

Immunocore Reports Second Quarter 2023 Financial Results and Provides Business Update

Immunocore Holdings plc announced its financial results for the second quarter ended June 30, 2023, and provided a business update.

August 10, 2023
·
23 min read
Business

Entrada Therapeutics Appoints Gina Chapman to its Board of Directors

Entrada Therapeutics, Inc., a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle -therapeutics as a new class of medicines, announced the appointment of Gina Chapman to its Board of Directors, effective September 1, 2023.

August 10, 2023
·
3 min read
Business

Altimmune Announces Second Quarter 2023 Financial Results and Provides a Business Update

Altimmune, Inc., a clinical-stage biopharmaceutical company, announced financial results for the three months ended June 30, 2023, and provided a business update.

August 10, 2023
·
10 min read
Business

Cabaletta Bio Reports Second Quarter 2023 Financial Results and Provides Business Update

Cabaletta Bio, Inc., a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, reported financial results for the second quarter ended June 30, 2023, and provided a business update.

August 10, 2023
·
12 min read
Business

Gain Therapeutics Announces Second Quarter 2023 Financial Results and Business Update

Gain Therapeutics, Inc., a biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, announced financial results for the second quarter ended June 30, 2023, and highlighted recent corporate progress.

August 10, 2023
·
10 min read
Business

TScan Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of T cell receptor-engineered T cell therapies for the treatment of patients with cancer, reported financial results and provided a corporate update for the second quarter ended June 30, 2023.

August 10, 2023
·
12 min read
Business

Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2023 Financial Results

Cullinan Oncology, Inc. a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, reported on recent and upcoming business highlights and announced its financial results for the second quarter ended June 30, 2023.

August 10, 2023
·
11 min read
Business

Larimar Therapeutics Reports Second Quarter 2023 Operating and Financial Results

Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today reported its second quarter operating and financial results.

August 10, 2023
·
11 min read
Business

Optinose Reports Second Quarter 2023 Financial Results and Operational Updates

Optinose, a pharmaceutical company focused on patients treated by ear, nose and throat and allergy specialists, reported financial results for the quarter ended June 30, 2023, and provided operational updates.

August 10, 2023
·
12 min read